OSU K12 Training Grant for Clinical Faculty Investigators

OSU K12 临床教师研究人员培训补助金

• 批准号: 8853828
• 负责人: JOHN C. BYRD
• 金额: $ 80.61万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-09 至 2019-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8853828
• 关键词: Applied Research; Basic Science; Clinical; Clinical Investigator; Clinical Oncology Supplement (K12); Clinical Research; Comprehensive Cancer Center; Critiques; Doctor of Philosophy; Education; Ensure; Faculty; Fellowship; Financial Support; Goals; Grant; Hematology; Individual; Investigation; Laboratories; Malignant Neoplasms; Medical Oncology; Medicine; Mentors; Minority; Nursing Faculty; Ohio; Patients; Peer Review; Phase II/III Trial; Program Evaluation; Radiation Oncology; Recruitment Activity; Research; Research Personnel; Resources; SECTM1 gene; Scientist; Solid Neoplasm; Surgical Oncology; Teacher Professional Development; Therapeutic; Training; Training Programs; Training and Education; Translational Research; Universities; Woman; base; cancer prevention; career; career development; drug development; interest; oncology; professor; programs; success; survivorship

DESCRIPTION (provided by applicant): The goal of this proposal is to mentor and effectively train faculty-level investigators in basic science and/or clinically-oriented approaches to translational research. Implementation of this K12 award for the career development of basic translational scientists (PhD, DVM, and MD) and clinical translational scientists (MD and MD/PhD) in Hematologic Oncology, Medical Oncology, Radiation Oncology and Surgical Oncology will ensure a cadre of highly-trained individuals dedicated to drug development as well as cancer prevention, control, and survivorship research. This K12 renewal from The Ohio State University Comprehensive Cancer Center (OSUCCC) continues its training focus on early drug development along with larger phase II/III trials, but now also extends to cancer prevention, control and survivorship research based on the previous critique. Focus on recruitment of scholars with interest in common solid tumors is also emphasized, as suggested. The OSUCCC is clearly dedicated to research education and providing outstanding training and mentoring opportunities to promising junior faculty. The OSU Divisions of Hematology, Medical Oncology, Radiation Oncology, and Surgical Oncology each have robust fellowship training programs that are continuously recruiting new junior faculty to facilitate expansion of our cancer program. Recruitment from other fellowship training programs also occurs, with particular focus on identification of women, minorities and people of different ethnic backgrounds to increase diversity. This K12 grant fills an important need by extending research education, training and mentoring to junior faculty interested in developing academic careers focused on clinical research. Moreover, it will be the only OSUCCC training program solely dedicated to career development in cancer at the faculty level, and therefore has no overlap with any of the OSU T32 training grants focused on fellows. This strategy will ensure continuity in training and provide individuals with the ability to become independent clinical investigators. Based upon the overall strength and direction of the OSUCCC, as demonstrated by its recent peer review score of 12 (exceptional), financial support of this K12 by OSUCCC, financial support by different Divisions and Departments, and breadth of resources available at OSU, this K12 proposal seeks to train primarily two types of assistant professors. The first group includes MD or PhD faculty (basic translational trainees) who have outstanding basic science training and desire to pursue laboratory investigation related to applied research in experimental therapeutics as well as cancer prevention, control, and survivorship. The second group includes MD or MD/PhD faculty (clinical translational trainees) who pursue patient-related research in clinically-focused experimental therapeutics and cancer prevention, control, or survivorship. Training plans tailored to each of these individual trainees will facilitate their success, with inclusion of a roust evaluation program to assess the success of the K12. This is best demonstrated by all of the current and past K12 scholars remaining in academic medicine and moving forward as independent clinical investigators.

描述（由申请人提供）：该提案的目标是在基础科学和/或临床导向的转化研究方法方面指导和有效培训教师级别的研究人员。为血液肿瘤学、肿瘤内科、放射肿瘤学和肿瘤外科领域的基础转化科学家（博士、DVM 和 MD）和临床转化科学家（MD 和 MD/PhD）的职业发展设立 K12 奖项，将确保培养一支训练有素的人才队伍，致力于药物开发以及癌症预防、控制和生存研究。俄亥俄州立大学综合癌症中心 (OSUCCC) 的 K12 更新继续将其培训重点放在早期药物开发以及更大规模的 II/III 期试验上，但现在还根据之前的批评扩展到癌症预防、控制和生存研究。正如建议的那样，还强调注重招募对常见实体瘤感兴趣的学者。 OSUCCC 显然致力于研究教育，并为有前途的初级教师提供出色的培训和指导机会。俄勒冈州立大学的血液学、肿瘤内科、放射肿瘤学和肿瘤外科各院系都有强大的进修培训计划，不断招募新的初级教师，以促进我们癌症项目的扩展。还从其他奖学金培训计划中招募人员，特别注重识别妇女、少数群体和不同种族背景的人，以增加多样性。这项 K12 拨款通过向有兴趣发展专注于临床研究的学术职业的初级教师提供研究教育、培训和指导，满足了一项重要需求。此外，这将是唯一一个专门致力于教师级别癌症职业发展的 OSUCCC 培训计划，因此与任何专注于研究员的 OSU T32 培训补助金都没有重叠。该策略将确保培训的连续性，并为个人提供成为独立临床研究人员的能力。基于 OSUCCC 的整体实力和方向，如最近的同行评审分数为 12（优异）、OSUCCC 对 K12 的财政支持、不同部门和部门的财政支持以及 OSU 可用资源的广度，本 K12 提案旨在主要培训两类助理教授。第一组包括医学博士或博士教师（基础转化实习生），他们接受过出色的基础科学训练，渴望从事与实验治疗学以及癌症预防、控制和生存方面的应用研究相关的实验室研究。第二组包括医学博士或医学博士/博士教师（临床转化实习生），他们在以临床为中心的领域从事与患者相关的研究 实验疗法和癌症预防、控制或生存。为每位学员量身定制的培训计划将促进他们的成功，其中包括评估 K12 成功与否的 rust 评估计划。所有当前和过去的 K12 学者都留在学术医学领域并作为独立的临床研究人员前进，这一点得到了最好的证明。